EHA 2023 | Treatment strategies for patients with IDH1/2-mutated AML ineligible for intensive chemotherapy
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses treatment strategies for patients with IDH1- and IDH2-mutated acute myeloid leukemia (AML) who are ineligible for intensive frontline chemotherapy. Dr Fathi first highlights the combination therapy azacitidine and venetoclax, which is effective in most patients with AML regardless of IDH status. However, in patients with IDH1-mutated AML, Dr Fathi explains that response rates and overall survival (OS) are high with the combination of azacitidine and the IDH1 inhibitor ivosidenib. Dr Fathi further notes a Phase II study which investigated treatment with azacitidine and the IDH2 inhibitor enasidenib in patients with IDH2-mutated AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Abbvie, Servier, BMS, Astellas, Takeda, Genentech, Remix, Ipsen, Rigel, Menarini, Daiichi Sankyo, Orum, Amgen, Pfizer, Autolus, Forma, PureTech, and Mablytics. Clinical trial support from BMS, Servier, and Abbvie.
